Lenalidomide induces remission and mixed quantitative chimerism fluctuations in refractory and relapsed myeloid malignancy with del (5).
Dumas
Pierre-Yves
PY
Pigneux
Arnaud
A
Tabrizi
Reza
R
Milpied
Noel
N
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D046528:Chimerism; D002872:Chromosome Deletion; D006801:Humans; D000077269:Lenalidomide; D008297:Male; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000235:genetics; D012074:Remission Induction / Q000379:methods; D016879:Salvage Therapy / Q000379:methods; D017384:Sequence Deletion; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000970:Antineoplastic Agents; D013792:Thalidomide; D000077269:Lenalidomide